🔎 Trials Near Me

Home › Kanser sa Baga › Maine

Pag-aaral pangklinika para sa Kanser sa Baga sa Maine

12 pag-aaral para sa Kanser sa Baga ang naghahanap ng mga kalahok sa mga site sa Maine.

Mga Lungsod sa Maine

Opisyal na teksto ng pag-aaral (English)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Harold Alfond Center for Cancer Care, Augusta
  • MaineHealth Waldo Hospital, Belfast
  • Lafayette Family Cancer Center-EMMC, Brewer
  • at 5 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT04267848

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

  • Lafayette Family Cancer Center-EMMC, Brewer
Nagre-recruitPhase 3
Edad 70 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06096844

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • Harold Alfond Center for Cancer Care, Augusta
  • MaineHealth Maine Medical Center- Scarborough, Scarborough
  • MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06498635

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Maine Medical Center, Portland
  • MaineHealth Cancer Care and Blood Disorders Scarborough, Scarborough
  • MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06758401

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Harold Alfond Center for Cancer Care, Augusta
  • MaineHealth Waldo Hospital, Belfast
  • Lafayette Family Cancer Center-EMMC, Brewer
  • at 9 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT05334069

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  • MaineHealth Maine Medical Center - Portland, Portland
  • MaineHealth Cancer Care Center of York County, Sanford
  • MaineHealth Maine Medical Center- Scarborough, Scarborough
  • at 1 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT05624996

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • Lafayette Family Cancer Center-EMMC, Brewer
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 3, 2026 · NCT05642572

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • Harold Alfond Center for Cancer Care, Augusta
  • MaineHealth Waldo Hospital, Belfast
  • Lafayette Family Cancer Center-EMMC, Brewer
  • at 5 pa
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update May 5, 2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Lafayette Family Cancer Center-EMMC, Brewer
Nagre-recruitPhase 2
18 Minutes · Lahat ng kasarian · Na-update May 5, 2026 · NCT06031688

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Scarborough
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.